The 5-year OS across all patients was 98.3% (95% CI 96.4-99.2%). A total of 24 deaths were reported, with 7 confirmed as lymphoma specific. OS was not significantly worse for patients who relapsed within 1 year (p=0.37) or 2 years (p=0.16) of initial diagnosis.
The rates of grade 1 to 3 toxicities were 37.6% for radiotherapy only, 39.2% for radiotherapy plus chemotherapy, 59.3% for chemotherapy only, and 26.3% for rituximab and radiotherapy.
Dr. Binkley told ASH Clinical News that the study was limited by its retrospective nature, as well as the lack of central pathology review. “Outside of a prospective clinical trial, future studies focusing on NLPHL should strive to have central pathology review to confirm diagnosis and score the immunoarchitectural pattern,†he said.